a Université de Toulouse III , Toulouse , France.
b Service de psychiatrie et psychologie , CHU Toulouse , Toulouse , France.
J Dual Diagn. 2019 Apr-Jun;15(2):118-121. doi: 10.1080/15504263.2019.1574367. Epub 2019 Mar 4.
Nalmefene is a kappa-opioid receptor agonist/antagonist which is currently prescribed to reduce heavy drinking days. Adverse events (AEs) have previously been described in trials, but these trials excluded patients with psychiatric comorbidities. This is important as psychiatric disorders are frequently associated with alcohol use disorders; therefore, the specific AEs in this population should be investigated. Here, we describe the case of a patient with diagnosed alcohol use disorder and schizoaffective disorder who received treatment with nalmefene. The patient showed decompensation of psychotic symptoms after two doses of medication, consisting of auditory hallucinations, delusions, and ideas of persecution. The symptoms improved two days after treatment discontinuation. This case indicates that the AEs of nalmefene should be specifically investigated in patients with psychiatric disorders.
纳美芬是一种κ-阿片受体激动剂/拮抗剂，目前被用于减少重度饮酒天数。先前的试验已经描述了不良反应（AE），但这些试验排除了有精神共病的患者。这很重要，因为精神障碍通常与酒精使用障碍有关；因此，应研究该人群中的特定不良反应。在这里，我们描述了一名被诊断为酒精使用障碍和分裂情感障碍的患者接受纳美芬治疗的情况。该患者在服用两剂药物后出现精神症状恶化，包括幻听、妄想和被害观念。停药两天后症状改善。该病例表明，应特别在有精神障碍的患者中研究纳美芬的不良反应。
